STAAR Surgical Marketing Mix
Built for Strategy. Ready in Minutes.
Discover how STAAR Surgical’s product innovation, targeted pricing, distribution through specialist channels, and clinical-focused promotions combine to drive adoption in ophthalmic markets. This concise 4Ps snapshot highlights competitive strengths and gaps, then directs you to the full, editable Marketing Mix Analysis for deeper data, strategic recommendations, and ready-to-use slides. Purchase the complete report to save research time and apply proven tactics immediately.
Product
EVO/Visian ICL portfolio
STAAR’s core offering is the EVO/Visian ICL family of implantable collamer lenses that correct myopia, hyperopia and astigmatism via intraocular implantation. The EVO/Visian ICL is positioned as a premium, reversible alternative to laser vision correction emphasizing high-quality optics and minimal induced dry eye. Marketing highlights reversibility, stable refractive outcomes and patient suitability when corneal ablation is contraindicated.
Toric and high-range corrections
Toric ICLs correct astigmatism alongside spherical errors, expanding candidacy beyond pure myopes. High-diopter options reach patients outside typical laser ranges, enabling treatment of extreme refractive errors. This breadth lets clinics manage complex refractive profiles and increases case mix. It differentiates STAAR by refractive breadth and clinical versatility.
Collamer material & lens design
Proprietary Collamer blends collagen copolymer for high biocompatibility and optical clarity, minimizing tissue response while maintaining refractive stability. Lens geometry promotes predictable, stable vaulting over the crystalline lens to reduce cataract risk and refractive surprises. Central port design (0.36 mm KS-Aquaport) supports physiological aqueous flow, improving safety and IOP predictability. Performance targets safety, predictability, and superior visual quality.
Cataract IOLs and supporting optics
STAAR also offers cataract IOLs and supporting optics that complement its refractive ICL portfolio, enabling surgeons to manage refractive and cataract cases across the patient vision-care journey. With over 20 million cataract surgeries globally annually (WHO range 2022–24) and a global IOL market ~3.7 billion USD in 2024, this diversification hedges procedural mix and broadens account relevance while reinforcing STAAR brand equity in premium intraocular optics.
- Product role: Cataract IOLs complement ICLs
- Market context: >20M surgeries/yr (WHO 2022–24)
- Market size: ~3.7B USD IOL market (2024)
- Strategic benefit: diversifies revenue base, strengthens premium optics positioning
Delivery systems and customization
Single-use injectors provide controlled Visian ICL insertion and reduce contamination risk, supporting predictable placement; lenses are sized using biometric inputs such as white-to-white and anterior chamber depth to optimize vault. Custom sterile packaging and procedure customization improve OR efficiency and visual outcomes; STAAR has delivered over 1 million implants worldwide by 2024.
- Controlled insertion via single-use injectors
- Biometric sizing (WTW, ACD) to optimize vault
- Sterile, customized packaging for surgical efficiency
- System-level value beyond implant
EVO/Visian ICLs: reversible, biocompatible vision correction with OR-ready injectors
STAAR’s EVO/Visian ICL family delivers premium, reversible correction for myopia, hyperopia and astigmatism with Collamer biocompatibility, central port safety and predictable vaulting. Single-use injectors, biometric sizing and sterile packaging support OR efficiency and outcomes. Portfolio includes cataract IOLs, diversifying exposure amid a ~3.7B USD IOL market and >20M cataract surgeries/yr; >1M ICLs implanted by 2024.
| Metric | Value | Source (yr) |
|---|---|---|
| ICL implants | >1,000,000 | STAAR (2024) |
| IOL market | ~3.7B USD | Market data (2024) |
| Cataract surgeries/yr | >20,000,000 | WHO (2022–24) |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific deep dive into STAAR Surgical’s Product, Price, Place, and Promotion strategies, using real brand practices and competitive context to ground recommendations for managers, consultants, and marketers.
Customizable Excel Spreadsheet
Condenses STAAR Surgical's 4P marketing analysis into a concise, actionable snapshot that relieves stakeholder pain by clarifying pricing, product positioning, promotion channels, and placement strategy for faster decisions and cross‑functional alignment. Ideal for leadership briefings, rapid strategy sessions, and plug‑and‑play inclusion in decks.
Place
Surgeon-only clinical channel
Surgeon-only clinical channel supplies ICLs exclusively to board-certified ophthalmic surgeons and refractive centers, targeting practices equipped for intraocular procedures. Direct engagement with clinics and surgeon training supports proper indication and patient selection, underpinning safety and outcomes. The channel has supported hundreds of thousands of EVO/ICl procedures globally, preserving product integrity and clinical results.
Global distributors and direct sales
STAAR Surgical uses a hybrid go-to-market model with direct sales in key markets and regional distributors covering 75+ countries. Local partners handle in-country logistics, regulatory compliance, and service, shortening time-to-patient and reducing operational complexity. Coverage spans North America, EMEA, APAC, and Latin America, balancing broad reach with specialist local support.
Regulatory and market access
Availability is tied to jurisdictional regulatory approvals, notably FDA clearance for the EVO ICL in 2022, with STAAR's portfolio now sold in 75+ countries. Market entry is sequenced via regulatory approval, local reimbursement pathways and KOL adoption to drive uptake. Labeling and surgeon training are localized to local standards and languages. This framework supports compliant, consistent clinical use and broader adoption.
Made-to-order and inventory hubs
Made-to-order sizing for STAAR Surgical products links SKUs to patient biometrics, so many lenses are built-to-order and tracked by batch; regional inventory hubs and demand forecasting shorten delivery for common sizes and support OR schedules. Sterile handling and tight shelf-life controls are standard; cold-chain is generally not required.
- Built-to-order SKUs tied to biometric data
- Regional hubs + forecasting reduce lead times
- Sterile handling; strict shelf-life management
- Fulfillment aligned to OR timing
In-theater training and service
Surgeon-channel ICL supply: built-to-order biometrics, regional hubs, FDA cleared (2018, 2022)
Surgeon-only clinical channel supplies ICLs to board-certified ophthalmic surgeons and refractive centers, supported by direct sales in key markets and distributors across 75+ countries. Built-to-order SKUs tied to biometrics use regional hubs and forecasting to shorten lead times for hundreds of thousands of global EVO/ICL procedures. FDA clearances: EVO 2022; Visian ICL 2018.
| Metric | Value |
|---|---|
| Geographic reach | 75+ countries |
| Procedures (cumulative) | Hundreds of thousands |
| Go‑to‑market | Direct + regional distributors |
| Key FDA dates | EVO 2022; Visian 2018 |
Same Document Delivered
STAAR Surgical 4P's Marketing Mix Analysis
The preview shown here is the actual STAAR Surgical 4P's Marketing Mix Analysis you'll receive instantly after purchase—no surprises. This same comprehensive, editable document covers Product, Price, Place and Promotion and is fully complete and ready to use. Download the exact file shown here immediately after checkout.
Built for Strategy. Ready in Minutes.
Discover how STAAR Surgical’s product innovation, targeted pricing, distribution through specialist channels, and clinical-focused promotions combine to drive adoption in ophthalmic markets. This concise 4Ps snapshot highlights competitive strengths and gaps, then directs you to the full, editable Marketing Mix Analysis for deeper data, strategic recommendations, and ready-to-use slides. Purchase the complete report to save research time and apply proven tactics immediately.
Product
EVO/Visian ICL portfolio
STAAR’s core offering is the EVO/Visian ICL family of implantable collamer lenses that correct myopia, hyperopia and astigmatism via intraocular implantation. The EVO/Visian ICL is positioned as a premium, reversible alternative to laser vision correction emphasizing high-quality optics and minimal induced dry eye. Marketing highlights reversibility, stable refractive outcomes and patient suitability when corneal ablation is contraindicated.
Toric and high-range corrections
Toric ICLs correct astigmatism alongside spherical errors, expanding candidacy beyond pure myopes. High-diopter options reach patients outside typical laser ranges, enabling treatment of extreme refractive errors. This breadth lets clinics manage complex refractive profiles and increases case mix. It differentiates STAAR by refractive breadth and clinical versatility.
Collamer material & lens design
Proprietary Collamer blends collagen copolymer for high biocompatibility and optical clarity, minimizing tissue response while maintaining refractive stability. Lens geometry promotes predictable, stable vaulting over the crystalline lens to reduce cataract risk and refractive surprises. Central port design (0.36 mm KS-Aquaport) supports physiological aqueous flow, improving safety and IOP predictability. Performance targets safety, predictability, and superior visual quality.
Cataract IOLs and supporting optics
STAAR also offers cataract IOLs and supporting optics that complement its refractive ICL portfolio, enabling surgeons to manage refractive and cataract cases across the patient vision-care journey. With over 20 million cataract surgeries globally annually (WHO range 2022–24) and a global IOL market ~3.7 billion USD in 2024, this diversification hedges procedural mix and broadens account relevance while reinforcing STAAR brand equity in premium intraocular optics.
- Product role: Cataract IOLs complement ICLs
- Market context: >20M surgeries/yr (WHO 2022–24)
- Market size: ~3.7B USD IOL market (2024)
- Strategic benefit: diversifies revenue base, strengthens premium optics positioning
Delivery systems and customization
Single-use injectors provide controlled Visian ICL insertion and reduce contamination risk, supporting predictable placement; lenses are sized using biometric inputs such as white-to-white and anterior chamber depth to optimize vault. Custom sterile packaging and procedure customization improve OR efficiency and visual outcomes; STAAR has delivered over 1 million implants worldwide by 2024.
- Controlled insertion via single-use injectors
- Biometric sizing (WTW, ACD) to optimize vault
- Sterile, customized packaging for surgical efficiency
- System-level value beyond implant
EVO/Visian ICLs: reversible, biocompatible vision correction with OR-ready injectors
STAAR’s EVO/Visian ICL family delivers premium, reversible correction for myopia, hyperopia and astigmatism with Collamer biocompatibility, central port safety and predictable vaulting. Single-use injectors, biometric sizing and sterile packaging support OR efficiency and outcomes. Portfolio includes cataract IOLs, diversifying exposure amid a ~3.7B USD IOL market and >20M cataract surgeries/yr; >1M ICLs implanted by 2024.
| Metric | Value | Source (yr) |
|---|---|---|
| ICL implants | >1,000,000 | STAAR (2024) |
| IOL market | ~3.7B USD | Market data (2024) |
| Cataract surgeries/yr | >20,000,000 | WHO (2022–24) |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific deep dive into STAAR Surgical’s Product, Price, Place, and Promotion strategies, using real brand practices and competitive context to ground recommendations for managers, consultants, and marketers.
Customizable Excel Spreadsheet
Condenses STAAR Surgical's 4P marketing analysis into a concise, actionable snapshot that relieves stakeholder pain by clarifying pricing, product positioning, promotion channels, and placement strategy for faster decisions and cross‑functional alignment. Ideal for leadership briefings, rapid strategy sessions, and plug‑and‑play inclusion in decks.
Place
Surgeon-only clinical channel
Surgeon-only clinical channel supplies ICLs exclusively to board-certified ophthalmic surgeons and refractive centers, targeting practices equipped for intraocular procedures. Direct engagement with clinics and surgeon training supports proper indication and patient selection, underpinning safety and outcomes. The channel has supported hundreds of thousands of EVO/ICl procedures globally, preserving product integrity and clinical results.
Global distributors and direct sales
STAAR Surgical uses a hybrid go-to-market model with direct sales in key markets and regional distributors covering 75+ countries. Local partners handle in-country logistics, regulatory compliance, and service, shortening time-to-patient and reducing operational complexity. Coverage spans North America, EMEA, APAC, and Latin America, balancing broad reach with specialist local support.
Regulatory and market access
Availability is tied to jurisdictional regulatory approvals, notably FDA clearance for the EVO ICL in 2022, with STAAR's portfolio now sold in 75+ countries. Market entry is sequenced via regulatory approval, local reimbursement pathways and KOL adoption to drive uptake. Labeling and surgeon training are localized to local standards and languages. This framework supports compliant, consistent clinical use and broader adoption.
Made-to-order and inventory hubs
Made-to-order sizing for STAAR Surgical products links SKUs to patient biometrics, so many lenses are built-to-order and tracked by batch; regional inventory hubs and demand forecasting shorten delivery for common sizes and support OR schedules. Sterile handling and tight shelf-life controls are standard; cold-chain is generally not required.
- Built-to-order SKUs tied to biometric data
- Regional hubs + forecasting reduce lead times
- Sterile handling; strict shelf-life management
- Fulfillment aligned to OR timing
In-theater training and service
Surgeon-channel ICL supply: built-to-order biometrics, regional hubs, FDA cleared (2018, 2022)
Surgeon-only clinical channel supplies ICLs to board-certified ophthalmic surgeons and refractive centers, supported by direct sales in key markets and distributors across 75+ countries. Built-to-order SKUs tied to biometrics use regional hubs and forecasting to shorten lead times for hundreds of thousands of global EVO/ICL procedures. FDA clearances: EVO 2022; Visian ICL 2018.
| Metric | Value |
|---|---|
| Geographic reach | 75+ countries |
| Procedures (cumulative) | Hundreds of thousands |
| Go‑to‑market | Direct + regional distributors |
| Key FDA dates | EVO 2022; Visian 2018 |
Same Document Delivered
STAAR Surgical 4P's Marketing Mix Analysis
The preview shown here is the actual STAAR Surgical 4P's Marketing Mix Analysis you'll receive instantly after purchase—no surprises. This same comprehensive, editable document covers Product, Price, Place and Promotion and is fully complete and ready to use. Download the exact file shown here immediately after checkout.
Original: $10.00
-65%$10.00
$3.50Description
Built for Strategy. Ready in Minutes.
Discover how STAAR Surgical’s product innovation, targeted pricing, distribution through specialist channels, and clinical-focused promotions combine to drive adoption in ophthalmic markets. This concise 4Ps snapshot highlights competitive strengths and gaps, then directs you to the full, editable Marketing Mix Analysis for deeper data, strategic recommendations, and ready-to-use slides. Purchase the complete report to save research time and apply proven tactics immediately.
Product
EVO/Visian ICL portfolio
STAAR’s core offering is the EVO/Visian ICL family of implantable collamer lenses that correct myopia, hyperopia and astigmatism via intraocular implantation. The EVO/Visian ICL is positioned as a premium, reversible alternative to laser vision correction emphasizing high-quality optics and minimal induced dry eye. Marketing highlights reversibility, stable refractive outcomes and patient suitability when corneal ablation is contraindicated.
Toric and high-range corrections
Toric ICLs correct astigmatism alongside spherical errors, expanding candidacy beyond pure myopes. High-diopter options reach patients outside typical laser ranges, enabling treatment of extreme refractive errors. This breadth lets clinics manage complex refractive profiles and increases case mix. It differentiates STAAR by refractive breadth and clinical versatility.
Collamer material & lens design
Proprietary Collamer blends collagen copolymer for high biocompatibility and optical clarity, minimizing tissue response while maintaining refractive stability. Lens geometry promotes predictable, stable vaulting over the crystalline lens to reduce cataract risk and refractive surprises. Central port design (0.36 mm KS-Aquaport) supports physiological aqueous flow, improving safety and IOP predictability. Performance targets safety, predictability, and superior visual quality.
Cataract IOLs and supporting optics
STAAR also offers cataract IOLs and supporting optics that complement its refractive ICL portfolio, enabling surgeons to manage refractive and cataract cases across the patient vision-care journey. With over 20 million cataract surgeries globally annually (WHO range 2022–24) and a global IOL market ~3.7 billion USD in 2024, this diversification hedges procedural mix and broadens account relevance while reinforcing STAAR brand equity in premium intraocular optics.
- Product role: Cataract IOLs complement ICLs
- Market context: >20M surgeries/yr (WHO 2022–24)
- Market size: ~3.7B USD IOL market (2024)
- Strategic benefit: diversifies revenue base, strengthens premium optics positioning
Delivery systems and customization
Single-use injectors provide controlled Visian ICL insertion and reduce contamination risk, supporting predictable placement; lenses are sized using biometric inputs such as white-to-white and anterior chamber depth to optimize vault. Custom sterile packaging and procedure customization improve OR efficiency and visual outcomes; STAAR has delivered over 1 million implants worldwide by 2024.
- Controlled insertion via single-use injectors
- Biometric sizing (WTW, ACD) to optimize vault
- Sterile, customized packaging for surgical efficiency
- System-level value beyond implant
EVO/Visian ICLs: reversible, biocompatible vision correction with OR-ready injectors
STAAR’s EVO/Visian ICL family delivers premium, reversible correction for myopia, hyperopia and astigmatism with Collamer biocompatibility, central port safety and predictable vaulting. Single-use injectors, biometric sizing and sterile packaging support OR efficiency and outcomes. Portfolio includes cataract IOLs, diversifying exposure amid a ~3.7B USD IOL market and >20M cataract surgeries/yr; >1M ICLs implanted by 2024.
| Metric | Value | Source (yr) |
|---|---|---|
| ICL implants | >1,000,000 | STAAR (2024) |
| IOL market | ~3.7B USD | Market data (2024) |
| Cataract surgeries/yr | >20,000,000 | WHO (2022–24) |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific deep dive into STAAR Surgical’s Product, Price, Place, and Promotion strategies, using real brand practices and competitive context to ground recommendations for managers, consultants, and marketers.
Customizable Excel Spreadsheet
Condenses STAAR Surgical's 4P marketing analysis into a concise, actionable snapshot that relieves stakeholder pain by clarifying pricing, product positioning, promotion channels, and placement strategy for faster decisions and cross‑functional alignment. Ideal for leadership briefings, rapid strategy sessions, and plug‑and‑play inclusion in decks.
Place
Surgeon-only clinical channel
Surgeon-only clinical channel supplies ICLs exclusively to board-certified ophthalmic surgeons and refractive centers, targeting practices equipped for intraocular procedures. Direct engagement with clinics and surgeon training supports proper indication and patient selection, underpinning safety and outcomes. The channel has supported hundreds of thousands of EVO/ICl procedures globally, preserving product integrity and clinical results.
Global distributors and direct sales
STAAR Surgical uses a hybrid go-to-market model with direct sales in key markets and regional distributors covering 75+ countries. Local partners handle in-country logistics, regulatory compliance, and service, shortening time-to-patient and reducing operational complexity. Coverage spans North America, EMEA, APAC, and Latin America, balancing broad reach with specialist local support.
Regulatory and market access
Availability is tied to jurisdictional regulatory approvals, notably FDA clearance for the EVO ICL in 2022, with STAAR's portfolio now sold in 75+ countries. Market entry is sequenced via regulatory approval, local reimbursement pathways and KOL adoption to drive uptake. Labeling and surgeon training are localized to local standards and languages. This framework supports compliant, consistent clinical use and broader adoption.
Made-to-order and inventory hubs
Made-to-order sizing for STAAR Surgical products links SKUs to patient biometrics, so many lenses are built-to-order and tracked by batch; regional inventory hubs and demand forecasting shorten delivery for common sizes and support OR schedules. Sterile handling and tight shelf-life controls are standard; cold-chain is generally not required.
- Built-to-order SKUs tied to biometric data
- Regional hubs + forecasting reduce lead times
- Sterile handling; strict shelf-life management
- Fulfillment aligned to OR timing
In-theater training and service
Surgeon-channel ICL supply: built-to-order biometrics, regional hubs, FDA cleared (2018, 2022)
Surgeon-only clinical channel supplies ICLs to board-certified ophthalmic surgeons and refractive centers, supported by direct sales in key markets and distributors across 75+ countries. Built-to-order SKUs tied to biometrics use regional hubs and forecasting to shorten lead times for hundreds of thousands of global EVO/ICL procedures. FDA clearances: EVO 2022; Visian ICL 2018.
| Metric | Value |
|---|---|
| Geographic reach | 75+ countries |
| Procedures (cumulative) | Hundreds of thousands |
| Go‑to‑market | Direct + regional distributors |
| Key FDA dates | EVO 2022; Visian 2018 |
Same Document Delivered
STAAR Surgical 4P's Marketing Mix Analysis
The preview shown here is the actual STAAR Surgical 4P's Marketing Mix Analysis you'll receive instantly after purchase—no surprises. This same comprehensive, editable document covers Product, Price, Place and Promotion and is fully complete and ready to use. Download the exact file shown here immediately after checkout.
